QuantuMDx and SCIENION Partner to Commercialize Novel Nanowire Biosensor
News Jun 09, 2015
QMDx utilizes SCIENION's proprietary ultra-low volume liquid handling technologies to transfer biological material onto QMDx's novel biosensor. Each nanowire in the array is printed with molecular probes; with hundreds of nanowires in each silicon biosensor chip, the multiplexing potential is massive.
The companies' longstanding relationship was cemented with QMDx's purchase of SCIENION's sciFLEXARRAYER SX, and will continue to grow as the companies embark on a number of development projects to take the biosensor characterization from R&D to mass manufacture.
The instrument is the newest fixture in QMDx's chemistry facility at the University of Newcastle upon Tyne's Chemical Nanoscience Laboratories.
QMDx's Head of Chemistry Dr Joseph Hedley said "The flexibility and ease of use of the sciFLEXARRAYER SX has enabled a rapid ramp up in QMDx's R&D activities, and we look forward to working with them on a number of exciting projects that will help bring this device to market."
"We're thrilled to be working with QuantuMDx" said Holger Eickhoff, CEO of SCIENION. "I look forward to our collaboration and believe that our work together will produce some fantastic developments that help foster some disruptive diagnostic innovations."
Stem Cells in Menstrual Blood Could Help Diagnose EndometriosisNews
The Feinstein Institute for Medical Research scientists announced an experimental, rapid and non-invasive way to diagnose endometriosis, which may lead to earlier and more effective treatments for this disorder that affects approximately 176 million women globally.READ MORE
SMi’s 5th Annual Molecular Diagnostics Conference 2018 Agenda ReleasedNews
SMi proudly presents its 5th annual conference on Molecular Diagnostics, taking place at the Holiday Inn Kensington Forum, London, UK on 9th and 10th July 2018, with a half-day post-conference workshops on 11th July 2018.READ MORE
Pap Test Fluids Used to Test for Endometrial & Ovarian CancersNews
Cervical fluid samples gathered during routine Papanicolaou (Pap) tests are the basis of a new screening test for endometrial and ovarian cancers developed by researchers at the Johns Hopkins Kimmel Cancer Center.